Literature DB >> 31437696

Can Machine Learning help us in dealing with treatment resistant depression? A review.

Alessandro Pigoni1, Giuseppe Delvecchio2, Domenico Madonna1, Cinzia Bressi1, Jair Soares3, Paolo Brambilla4.   

Abstract

BACKGROUND: About one third of patients treated with antidepressant do not show sufficient symptoms relief and up to 15% of patients remain symptomatic even after multiple trials are applied, configuring a state called treatment resistant depression (TRD). A clear definition of this state and the understanding of underlying mechanisms contributing to chronic disability caused by major depressive disorder is still unknown. Therefore, Machine Learning (ML) techniques emerged in the last years as interesting approaches to deal with such complex problems.
METHODS: We performed a bibliographic search on Pubmed, Google Scholar and Medline of clinical, imaging, genetic and EEG ML classification studies on treatment-responding depression and TRD as well as studies trying to predict response to a specific treatment in already established TRD. The inclusion criteria were met by eleven studies. Seven focused on the definition of predictors of TRD onset while four attempted to predict the response to specific treatments in TRD.
RESULTS: The results showed that it seems possible to classify between responders MDD and TRD with good accuracies based on clinical variables. Moreover, some studies reported the possibility of using EEG measures to predict response to different pharmacological and non-pharmacological treatments in established TRD. LIMITATIONS: The definition of TRD, the selection of variables together with ML algorithms and pipelines varies across the studies, ultimately determining the unfeasibility to implement these models in clinical practice.
CONCLUSIONS: The findings suggest that ML could be a valid approach to increase our understanding of TRD and to better classify and stratify this disorder, which may ultimately help clinicians in the assessment of major depressive disorders.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Depression; EEG; Imaging; Machine Learning; Major depressive disorder; Treatment resistant depression

Mesh:

Substances:

Year:  2019        PMID: 31437696     DOI: 10.1016/j.jad.2019.08.009

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  6 in total

1.  Depression and Severity Detection Based on Body Kinematic Features: Using Kinect Recorded Skeleton Data of Simple Action.

Authors:  Yanhong Yu; Wentao Li; Yue Zhao; Jiayu Ye; Yunshao Zheng; Xinxin Liu; Qingxiang Wang
Journal:  Front Neurol       Date:  2022-06-30       Impact factor: 4.086

2.  Predictors of Treatment Resistance Across Different Clinical Subtypes of Depression: Comparison of Unipolar vs. Bipolar Cases.

Authors:  Michele Fornaro; Andrea Fusco; Stefano Novello; Pierluigi Mosca; Annalisa Anastasia; Antonella De Blasio; Felice Iasevoli; Andrea de Bartolomeis
Journal:  Front Psychiatry       Date:  2020-05-15       Impact factor: 4.157

Review 3.  Psychiatry in the Digital Age: A Blessing or a Curse?

Authors:  Carl B Roth; Andreas Papassotiropoulos; Annette B Brühl; Undine E Lang; Christian G Huber
Journal:  Int J Environ Res Public Health       Date:  2021-08-05       Impact factor: 3.390

4.  Simple action for depression detection: using kinect-recorded human kinematic skeletal data.

Authors:  Wentao Li; Qingxiang Wang; Xin Liu; Yanhong Yu
Journal:  BMC Psychiatry       Date:  2021-04-22       Impact factor: 3.630

5.  Improving Mental Health Services: A 50-Year Journey from Randomized Experiments to Artificial Intelligence and Precision Mental Health.

Authors:  Leonard Bickman
Journal:  Adm Policy Ment Health       Date:  2020-09

6.  Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data.

Authors:  Dekel Taliaz; Amit Spinrad; Ran Barzilay; Zohar Barnett-Itzhaki; Dana Averbuch; Omri Teltsh; Roy Schurr; Sne Darki-Morag; Bernard Lerer
Journal:  Transl Psychiatry       Date:  2021-07-08       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.